Endpoints News – Biotech and pharma business news, with a focus …
US regulators have rejected a T cell therapy for a rare and serious transplant complication related to Epstein-Barr virus from Atara Biotherapeutics and ...
Endpoints at #BIO23: The dawn of a new biotech era
R&D chiefs are taking a hard look at what’s in the pipeline — and what’s out. Continuing our theme of the week, we’re talking to a group of pharma R&D chiefs about the way they are picking and choosing which drugs to push ahead.
New oncology biotech launches with $52M in its pocket
Dec 10, 2024 · A small molecule cancer biotech broke cover on Tuesday with a $52 million Series A to take on a “unique lipidation pocket” and get into …
Regeneron forges ahead in factor XI despite field’s mixed results
Dec 19, 2024 · Regeneron will start a 'broad' Phase 3 program next year for its two factor XI antibodies, following open-label Phase 2 results for the experimental anti-clotting drugs.
Endpoints at #JPM22 - A look at what's to come in 2022
A look at what's to come in 2022 Jan 10 through Jan 12 virtual event. The biopharma world kicks off each year with a frenzy of activity at JP Morgan. Endpoints has been there to chronicle it with wall-to-wall coverage, and our founder and editor John Carroll has convened top newsmakers to provide detailed insights about their strategies.
Vertex gets ‘vanza triple’ approval and Trikafta expansion
Dec 23, 2024 · The FDA on Friday issued two simultaneous cystic fibrosis approvals for Vertex Pharmaceuticals but included high-level safety warnings for both.
Biosecure Act influence still felt even as China bill stalls
Dec 18, 2024 · Congress excludes WuXi AppTec ban (Biosecure Act) from year-end package, but impact felt as Tectonic Therapeutic's CEO Alise Reicin and others shift from Chinese manufacturers.
Endpoints 11 - Biopharma's Most Promising Startups in 2021
The biotech 2.0 era has arrived. And with that backdrop, we'll unveil the top 11 companies supercharging a new generation of startups in 2021.
Pennsylvania Blue Cross insurer restricts coverage of medicines …
Jan 2, 2025 · A Blue Cross Blue Shield licensee serving parts of Pennsylvania says it will not cover some therapies granted accelerated approval for at least 18 months after the FDA signs off.
Novartis ends Phase 1 radiopharma trial; Solve Therapeutics …
Dec 27, 2024 · Ideaya Biosciences makes an ADC deal with Hengrui Pharma. Amylyx expands GLP-1 work with a new Gubra collaboration.